A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Part of paid clinical trials in East Hanover, New Jersey.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07635316
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 110 Years
Healthy Volunteers
Not accepted

Study Details

This study aims to characterize current treatment patterns and clinical outcomes among newly diagnosed GEP-NET patients in the United States using open-source Longitudinal Prescription Claims (LRx) and Patient Centric Medical Claims (Dx) databases supplemented with mortality data.

Key Dates

Start date
Jun 12, 2026
Status verified
Jul 2026
Primary completion
Feb 25, 2027
Completion
Feb 25, 2027

Study Design

Enrollment
4,023 participants (estimated)

Arms

  • Arm: Overall GEP-NET Cohort
    Adult patients newly diagnosed with a GEP-NET between 01 January 2018 and 31 December 2025.
  • Arm: 1L Lutetium Lu 177 Dotatate Cohort
    A subgroup of the Overall GEP-NET Cohort. Patients receiving 1L lutetium Lu 177 dotatate.
  • Arm: 1L Capecitabine + Temozolomide (CAPTEM) Cohort
    A subgroup of the Overall GEP-NET Cohort. Patients receiving 1L CAPTEM.
  • Arm: 1L Cabozantinib Cohort
    A subgroup of the Overall GEP-NET Cohort. Patients receiving 1L cabozantinib.
  • Arm: Lutetium Lu 177 Dotatate Cohort
    A subgroup of the Overall GEP-NET Cohort. Patients receiving lutetium Lu 177 dotatate in 2L or later settings.
  • Arm: CAPTEM Cohort
    A subgroup of the Overall GEP-NET Cohort. Patients receiving CAPTEM in 2L or later settings.
  • Arm: Cabozantinib Cohort
    A subgroup of the Overall GEP-NET Cohort. Patients receiving cabozantinib in 2L or later settings.

Primary Outcome Measure

Number of Lines of Therapy (LOTs) [ Time Frame: Up to approximately 8 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
NovartisEast HanoverNew Jersey07936-

Find similar trials in East Hanover, NJ

By condition
Neuroendocrine tumors
By specialty
Oncology
By research site
Novartis· East Hanover, NJ

Related Studies